Cargando…

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives

Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tovoli, Francesco, Negrini, Giulia, Benevento, Francesca, Faggiano, Chiara, Goio, Elisabetta, Granito, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168042/ https://www.ncbi.nlm.nih.gov/pubmed/30302192 http://dx.doi.org/10.2217/hep-2017-0020

Ejemplares similares

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery
por: Goio, Elisabetta, et al.
Publicado: (2020)

Hot topics in hepatocellular carcinoma
por: Ielasi, Luca, et al.
Publicado: (2019)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis
por: Tovoli, Francesco, et al.
Publicado: (2018)

Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods
por: Raiteri, Alberto, et al.
Publicado: (2022)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

Evolution of bone densitometry parameters and risk of fracture in coeliac disease: a 10-year perspective
por: Tovoli, Francesco, et al.
Publicado: (2023)

Current guidelines for the management of celiac disease: A systematic review with comparative analysis
por: Raiteri, Alberto, et al.
Publicado: (2022)

Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients?
por: Tovoli, Francesco, et al.
Publicado: (2022)

Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers
por: Renzulli, Matteo, et al.
Publicado: (2022)

Medical Treatment of Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2009)

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
por: Ielasi, Luca, et al.
Publicado: (2021)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool?
por: Renzulli, Matteo, et al.
Publicado: (2022)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Autoantibodies to speckled protein family in primary biliary cholangitis
por: Granito, Alessandro, et al.
Publicado: (2021)

Anti-ganglioside antibodies and celiac disease
por: Granito, Alessandro, et al.
Publicado: (2021)

Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5)
por: Terzi, Eleonora, et al.
Publicado: (2022)

Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Ferri, Silvia, et al.
Publicado: (2022)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients
por: Benevento, Francesca, et al.
Publicado: (2023)

Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
por: Garajová, Ingrid, et al.
Publicado: (2023)

COVID-19: Has the Liver Been Spared?
por: Brandi, Nicolò, et al.
Publicado: (2023)

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2015)

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
por: De Lorenzo, Stefania, et al.
Publicado: (2022)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence
por: Ferronato, Marco, et al.
Publicado: (2023)

Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
por: Marinelli, Sara, et al.
Publicado: (2013)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact
por: Federico, Piera, et al.
Publicado: (2022)

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
por: Pallozzi, Maria, et al.
Publicado: (2022)

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023)

Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma
por: Tsuchiya, Atsunori, et al.
Publicado: (2019)

Hepatocellular carcinoma: a systems biology perspective
por: D'Alessandro, Lorenza A., et al.
Publicado: (2013)

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
por: Xu, Weiqi, et al.
Publicado: (2019)

Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives
por: Rinninella, Emanuele, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n0muq6djusob5p6186gtf9rv8k